Entry |
|
Name |
Amplified FGFR to RAS-ERK signaling pathway
|
Definition |
FGFR* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK |
Expanded |
(2260v1,2263v1) -> 2885 -> (6654,6655) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595) |
Class |
|
Type |
Variant
|
Pathway |
|
Disease |
|
Gene |
2260 | FGFR1; fibroblast growth factor receptor 1 |
2263 | FGFR2; fibroblast growth factor receptor 2 |
2885 | GRB2; growth factor receptor bound protein 2 |
6654 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 |
6655 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 |
3265 | HRAS; HRas proto-oncogene, GTPase |
3845 | KRAS; KRAS proto-oncogene, GTPase |
4893 | NRAS; NRAS proto-oncogene, GTPase |
369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
5594 | MAPK1; mitogen-activated protein kinase 1 |
5595 | MAPK3; mitogen-activated protein kinase 3 |
|
Variant |
2260v1 (FGFR*) FGFR1 amplification
2263v1 (FGFR*) FGFR2 amplification
|
Reference |
|
Authors |
Zhang MH, Man HT, Zhao XD, Dong N, Ma SL |
Title |
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). |
Journal |
|
Reference |
|
Authors |
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A |
Title |
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. |
Journal |
|
Reference |
|
Authors |
Katoh M, Nakagama H |
Title |
FGF receptors: cancer biology and therapeutics. |
Journal |
|
Reference |
|
Authors |
Katoh M |
Title |
FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. |
Journal |
|
Reference |
|
Authors |
Katoh M |
Title |
Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. |
Journal |
|